These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 9222274)

  • 41. Subthalamic nucleus stimulation for Parkinson disease: benefits observed in levodopa-intolerant patients.
    Katayama Y; Kasai M; Oshima H; Fukaya C; Yamamoto T; Ogawa K; Mizutani T
    J Neurosurg; 2001 Aug; 95(2):213-21. PubMed ID: 11780890
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Various aspects of motor fluctuations and their management in Parkinson's disease.
    Mizuno Y; Kondo T; Mori H
    Neurology; 1994 Jul; 44(7 Suppl 6):S29-34. PubMed ID: 8047258
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Use of electroconvulsive therapy in Parkinson disease with residual axial symptoms partially unresponsive to L-dopa: a pilot study.
    Pintor LP; Valldeoriola F; Fernández-Egea E; Sánchez R; Rami L; Tolosa E; Muñiz A; Martí MJ; Bernardo M
    J ECT; 2012 Jun; 28(2):87-91. PubMed ID: 22531200
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Motor and mental complications in the long-term treatment of complicated Parkinson's disease with levodopa].
    Molina JA; Jiménez-Jiménez FJ; Ortí-Pareja M
    Rev Neurol; 1999 May 16-31; 28(10):982-90. PubMed ID: 10416237
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Benefit of L-DOPA-without-DCI (decarboxylase inhibitor) therapy on wearing-off phenomenon in advanced stages of Parkinson's disease patients].
    Hironishi M; Miwa H; Kondo T
    No To Shinkei; 2002 Feb; 54(2):127-32. PubMed ID: 11889758
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Medical management of advanced Parkinson's disease.
    Goudreau JL
    Clin Geriatr Med; 2006 Nov; 22(4):753-72, v. PubMed ID: 17000334
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The clinical spectrum of freezing of gait in Parkinson's disease.
    Okuma Y; Yanagisawa N
    Mov Disord; 2008; 23 Suppl 2():S426-30. PubMed ID: 18668623
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Parkinson's disease--Part 3: Neuropsychiatric symptoms.
    Weintraub D; Comella CL; Horn S
    Am J Manag Care; 2008 Mar; 14(2 Suppl):S59-69. PubMed ID: 18402509
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Treatment options for non-motor symptoms in late-stage Parkinson's disease.
    Coelho M; Ferreira J; Rosa M; Sampaio C
    Expert Opin Pharmacother; 2008 Mar; 9(4):523-35. PubMed ID: 18312155
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Non-motor extranigral signs and symptoms in Parkinson's disease.
    Wolters ECh
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S6-12. PubMed ID: 20083010
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Management of non-motor symptoms in advanced Parkinson disease.
    Truong DD; Bhidayasiri R; Wolters E
    J Neurol Sci; 2008 Mar; 266(1-2):216-28. PubMed ID: 17804018
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A reality test: How well do we understand psychosis in Parkinson's disease?
    Ismail MS; Richard IH
    J Neuropsychiatry Clin Neurosci; 2004; 16(1):8-18. PubMed ID: 14990754
    [TBL] [Abstract][Full Text] [Related]  

  • 54. REM sleep behavior disorder: association with motor complications and impulse control disorders in Parkinson's disease.
    Kim YE; Jeon BS; Yang HJ; Ehm G; Yun JY; Kim HJ; Kim JM
    Parkinsonism Relat Disord; 2014 Oct; 20(10):1081-4. PubMed ID: 25085747
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacokinetic and pharmacodynamic considerations in management of motor response fluctuations in Parkinson's disease.
    Cedarbaum JM
    Neurol Clin; 1990 Feb; 8(1):31-49. PubMed ID: 2181267
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A 12-year population-based study of freezing of gait in Parkinson's disease.
    Forsaa EB; Larsen JP; Wentzel-Larsen T; Alves G
    Parkinsonism Relat Disord; 2015 Mar; 21(3):254-8. PubMed ID: 25603767
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Health-related quality of life and healthcare utilisation in patients with Parkinson's disease: impact of motor fluctuations and dyskinesias.
    Dodel RC; Berger K; Oertel WH
    Pharmacoeconomics; 2001; 19(10):1013-38. PubMed ID: 11735671
    [TBL] [Abstract][Full Text] [Related]  

  • 58. New pharmacological options for treating advanced Parkinson's disease.
    Devos D; Moreau C; Dujardin K; Cabantchik I; Defebvre L; Bordet R
    Clin Ther; 2013 Oct; 35(10):1640-52. PubMed ID: 24011636
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Parkinson's disease: recent advances.
    Pandey S
    J Assoc Physicians India; 2012 Jun; 60():30-2. PubMed ID: 23409418
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Disability in Activities of Daily Living and Severity of Dyskinesias Determine the Handicap of Parkinson's Disease Patients in Advanced Stage Selected to DBS.
    Coelho M; Abreu D; Correia-Guedes L; Lobo PP; Fabbri M; Godinho C; Domingos J; Albuquerque L; Freitas V; Pereira JM; Cattoni B; Carvalho H; Reimão S; Rosa MM; Ferreira AG; Ferreira JJ
    J Parkinsons Dis; 2017; 7(2):255-261. PubMed ID: 28157106
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.